LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
CHICAGO, Feb. 25, 2016 -- Today, Allscripts (NASDAQ:MDRX) representatives Rich Elmore, Senior Vice President of Corporate Development and Strategy, and Leigh Burchell, Vice President of Health Policy and Government Affairs, will join President Barack Obama at the White House Precision Medicine Initiative (PMI) Summit. As a participant in the PMI, Allscripts will pilot use of open, standardized Application Programming Interfaces (APIs) with Allscripts FollowMyHealth® patient engagement platform to give individuals the ability to contribute their data to research, including the PMI Cohort Program when it is launched.
“By inviting patients to contribute their data to ground-breaking research efforts such as the PMI Cohort Program, this collaborative industry effort will speed progress in delivering the benefits of a precision medicine approach to healthcare professionals and patients alike,” Allscripts Chief Executive Officer Paul M. Black said. “Creating a national database with one million patients promises a more data-driven and personalized approach to treatment than exists today, and that is going to mean improved outcomes and a better care experience for patients.”
In addition to this initiative, Allscripts has demonstrated its commitment to precision medicine in several ways:
- Formed and funded in 2015, the Allscripts Precision Medicine business unit is mapping out the semantic integration of genomic research, personalized data and clinical information held within electronic health records (EHRs). The ultimate goal is to help clinicians make informed decisions by integrating complex data sets and delivering actionable insights at the point of care.
- Allscripts and NantHealth, a cloud-based information technology company founded by Dr. Patrick Soon-Shiong, MD, formed a strategic alliance in March of 2015. Together, the companies intend to develop an integrated, evidence-based personalized approach to healthcare solutions, starting with cancer care.
- Under Vice President Joe Biden’s leadership, the National Cancer Moonshot is a coalition working to help cancer fighters share information and accelerate research efforts. Allscripts helped inform the conversation with the Vice President and joins several organizations, including Allscripts Sunrise™ client National Institutes of Health (NIH), to speed the advance of cancer research over the next five years.
- Through the National Immunotherapy Coalition, Allscripts joins leaders from biotech and pharmaceutical companies, academic cancer centers and providers to validate the potential of combination immunotherapy as the next standard of care for cancer patients. The coalition aims to complete randomized Phase II trials in patients at all stages of disease in up to 20 tumor types in 20,000 patients within the next two years.
“The United States healthcare system does not deliver the best possible outcomes to patients, and a lot of unnecessary money is spent because of a one-size-fits-all approach to treating patients,” Senior Vice President and General Manager for Allscripts Precision Medicine Assaf Halevy, said. “The reality is that we can be more precise today with the knowledge we have. We believe that enabling genomic-based interventions at the point of care and in the clinician’s workflow will make treatment more precise.”
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
© 2016 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.
For more information contact: Investors: Seth Frank 312-506-1213 [email protected] Media: Concetta DiFranco 312-447-2466 [email protected]
